SCARB1 and neoplasm: This SR-B1 expression level was comparable to that of other tumor cell lines with known increased expression of SR-B1 and a favorable response to SR-B1 targeted therapeutic strategies, such as B16F10 and 4T1 (Figure 2A) [1,35,36].